Avalo Therapeutics (NASDAQ:AVTX) vs. SAB Biotherapeutics (NASDAQ:SABS) Head to Head Survey

SAB Biotherapeutics (NASDAQ:SABS) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares SAB Biotherapeutics and Avalo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Earnings & Valuation

This table compares SAB Biotherapeutics and Avalo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32 million	205.42	$13.27 million	($1.30)	-2.29
Avalo Therapeutics	$60,000.00	13,398.56	-$78.26 million	($4.37)	-3.43

SAB Biotherapeutics has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for SAB Biotherapeutics and Avalo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1	1	9	0	2.73
Avalo Therapeutics	1	0	12	0	2.85

SAB Biotherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 302.68%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 200.87%. Given SAB Biotherapeutics’ higher possible upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Avalo Therapeutics.

Volatility & Risk

SAB Biotherapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Summary

SAB Biotherapeutics beats Avalo Therapeutics on 8 of the 13 factors compared between the two stocks.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.